Across TCGA pan-cancer cohorts, FGF22 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FGF22 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in brain lower grade glioma (LGG), where higher FGF22 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FGF22 expression acts as an unfavorable survival marker.
LGG are the cancer types where FGF22 Mutation most reproducibly stratifies survival.